Compare AIRS & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRS | SMTI |
|---|---|---|
| Founded | 2012 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.7M | 313.5M |
| IPO Year | 2021 | 2008 |
| Metric | AIRS | SMTI |
|---|---|---|
| Price | $2.74 | $34.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 862.1K | 425.7K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $151,818,000.00 | $15,586,976.00 |
| Revenue This Year | $5.19 | $17.31 |
| Revenue Next Year | $5.32 | $12.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.47 |
| 52 Week Low | $1.51 | $16.05 |
| 52 Week High | $12.00 | $35.70 |
| Indicator | AIRS | SMTI |
|---|---|---|
| Relative Strength Index (RSI) | 34.17 | 79.57 |
| Support Level | $2.43 | $33.68 |
| Resistance Level | $3.36 | N/A |
| Average True Range (ATR) | 0.33 | 0.22 |
| MACD | -0.14 | -0.28 |
| Stochastic Oscillator | 11.30 | 95.77 |
AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Its proprietary and patented AirSculpt method is minimally invasive because it requires no needle, no scalpel, no stitches, and no general anesthesia. It offers fat removal procedures across treatment areas and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its segment is direct medical procedure services.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.